GOSS insider transaction filings
Gossamer Bio, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-26. Screen GOSS transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 7.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Giraudo Bryan — COO/CFO | 1 | — | — | 2 |
| Hasnain Faheem — President & CEO, Director | 1 | — | — | 2 |
| Christian Waage — EVP, Tech Ops and Admin | 1 | — | — | 1 |
| Peterson Caryn — Chief Development Officer | 1 | — | — | 1 |
| Smith Robert Paul JR — Chief Commercial Officer | 1 | — | — | 1 |
Recent Form 4 filings — Gossamer Bio, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-26 | 4 | Giraudo Bryan — COO/CFO | Grant/award (A): 25 (derivative) @ $1,000.00 · Grant/award (A): 5,800,051 (derivative) @ $0 | EDGAR |
| 2026-08-26 | 4 | Smith Robert Paul JR — Chief Commercial Officer | Grant/award (A): 5,800,051 (derivative) @ $0 | EDGAR |
| 2026-08-26 | 4 | Peterson Caryn — Chief Development Officer | Grant/award (A): 5,800,051 (derivative) @ $0 | EDGAR |
| 2026-08-26 | 4 | Christian Waage — EVP, Tech Ops and Admin | Grant/award (A): 2,900,026 (derivative) @ $0 | EDGAR |
| 2026-08-26 | 4 | Hasnain Faheem — President & CEO, Director | Grant/award (A): 166 (derivative) @ $1,000.00 · Grant/award (A): 5,800,051 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Nathan Steven D — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Drynan Skye — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Milligan Sandra — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Quisel John D — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Daniel Thomas O — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Cox Russell J. — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Smith Robert Paul JR — Chief Commercial Officer | Disposition to issuer (D): 562,500 (derivative) · Disposition to issuer (D): 572,000 (derivative) · Grant/award (A): 562,500 (derivative) · Grant/award (A): 572,000 (derivative) | EDGAR |
| 2026-03-20 | 4 | Aranda Richard — Chief Medical Officer | Disposition to issuer (D): 562,500 (derivative) · Disposition to issuer (D): 572,000 (derivative) · Disposition to issuer (D): 487,500 (derivative) · Disposition to issuer (D): 162,500 (derivative) · Disposition to issuer (D): 157,500 (derivative) · Disposition to issuer (D): 157,500 (derivative) · +18 more | EDGAR |
| 2026-03-20 | 4 | Peterson Caryn — EVP, Regulatory Affairs | Disposition to issuer (D): 506,250 (derivative) · Disposition to issuer (D): 440,000 (derivative) · Disposition to issuer (D): 375,000 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 157,500 (derivative) · Disposition to issuer (D): 157,500 (derivative) · +18 more | EDGAR |
| 2026-03-20 | 4 | Giraudo Bryan — COO/CFO | Disposition to issuer (D): 693,750 (derivative) · Disposition to issuer (D): 638,000 (derivative) · Disposition to issuer (D): 543,750 (derivative) · Disposition to issuer (D): 181,250 (derivative) · Disposition to issuer (D): 211,500 (derivative) · Disposition to issuer (D): 211,500 (derivative) · +16 more | EDGAR |
| 2026-03-20 | 4 | Christian Waage — EVP, Tech Ops and Admin | Disposition to issuer (D): 506,250 (derivative) · Disposition to issuer (D): 440,000 (derivative) · Disposition to issuer (D): 375,000 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 157,500 (derivative) · Disposition to issuer (D): 157,500 (derivative) · +14 more | EDGAR |
| 2026-03-20 | 4 | Hasnain Faheem — President & CEO, Director | Disposition to issuer (D): 1,680,000 (derivative) · Disposition to issuer (D): 1,540,000 (derivative) · Disposition to issuer (D): 1,312,500 (derivative) · Disposition to issuer (D): 437,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · +14 more | EDGAR |
| 2026-01-05 | 4 | Smith Robert Paul JR — Chief Commercial Officer | Grant/award (A): 93,750 @ $0 · Grant/award (A): 562,500 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Aranda Richard — Chief Medical Officer | Grant/award (A): 93,750 @ $0 · Grant/award (A): 562,500 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Peterson Caryn — EVP, Regulatory Affairs | Grant/award (A): 84,500 @ $0 · Grant/award (A): 506,250 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Giraudo Bryan — COO/CFO | Grant/award (A): 115,750 @ $0 · Grant/award (A): 693,750 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Christian Waage — EVP, Tech Ops and Admin | Grant/award (A): 84,500 @ $0 · Grant/award (A): 506,250 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Hasnain Faheem — President & CEO, Director | Grant/award (A): 280,000 @ $0 · Grant/award (A): 1,680,000 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Smith Robert Paul JR — Chief Commercial Officer | Grant/award (A): 162,500 @ $0 | EDGAR |
| 2025-10-02 | 4 | Aranda Richard — Chief Medical Officer | Grant/award (A): 162,500 @ $0 | EDGAR |
| 2025-10-02 | 4 | Peterson Caryn — EVP, Regulatory Affairs | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2025-10-02 | 4 | Giraudo Bryan — COO/CFO | Grant/award (A): 181,250 @ $0 | EDGAR |
| 2025-10-02 | 4 | Christian Waage — EVP, Tech Ops and Admin | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2025-10-02 | 4 | Hasnain Faheem — President & CEO, Director | Grant/award (A): 437,500 @ $0 | EDGAR |
| 2025-08-20 | 4 | Milligan Sandra — Director | Purchase (P): 26,050 @ $1.92 | EDGAR |
| 2025-06-26 | 4 | Nathan Steven D — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Milligan Sandra — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Drynan Skye — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Quisel John D — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Daniel Thomas O — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Cox Russell J. — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Peterson Caryn — EVP, Regulatory Affairs | Grant/award (A): 440,000 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Smith Robert Paul JR — Chief Commercial Officer | Grant/award (A): 572,000 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Aranda Richard — Chief Medical Officer | Grant/award (A): 572,000 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Giraudo Bryan — COO/CFO | Grant/award (A): 638,000 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Christian Waage — EVP, Tech Ops and Admin | Grant/award (A): 440,000 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Hasnain Faheem — President & CEO, Director | Grant/award (A): 1,540,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Aranda Richard — Chief Medical Officer | Sale (S): 1,908 @ $0.66 | EDGAR |
| 2024-06-24 | 4 | Hasnain Faheem — President & CEO, Director | Purchase (P): 372,000 @ $0.67 | EDGAR |
| 2024-06-20 | 4 | Giraudo Bryan — COO/CFO | Purchase (P): 100,000 @ $0.59 | EDGAR |
| 2024-06-20 | 4 | Smith Robert Paul JR — Chief Commercial Officer | Purchase (P): 25,000 @ $0.60 | EDGAR |
| 2024-06-06 | 4 | Milligan Sandra — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Quisel John D — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Daniel Thomas O — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Cox Russell J. — Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Gossamer Bio, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-11 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-03 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-26 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GOSS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →